Synopsis

Source of validity: Scientific
Rating (out of 5): 2

Curcuminoids, most notably curcumin from turmeric (Curcuma longa), have been studied for their anti-inflammatory and antioxidant properties, which are relevant to the pathophysiology of eczema (atopic dermatitis). Several preclinical studies (in vitro and animal models) suggest that curcumin can downregulate pro-inflammatory cytokines, suppress nuclear factor kappa B (NF-κB) activation, and mitigate oxidative stress, all of which are implicated in eczema. Some small human studies and case series have reported improvements in eczema symptoms with topical or oral curcumin/curcuminoid preparations. For example, a double-blind, randomized controlled pilot study (Kumar et al., 2016) found that topical application of a turmeric-based cream resulted in significant improvement of symptoms compared to placebo. However, the number of high-quality, large-scale clinical trials remains very limited, and formulations, dosages, and outcome measures vary substantially among studies. As such, while there is a scientific rationale and some preliminary evidence supporting curcuminoids for eczema, the overall strength of the clinical evidence is low, and more rigorous research is needed to establish efficacy and safety. Thus, the use of curcuminoids in eczema is justified by scientific rationale and early evidence, but current support is modest.

More about Curcuminoid (unspecified)
More about Eczema

Other ingredients used for Eczema

Other health conditions supported by Curcuminoid (unspecified)

Products containing Curcuminoid (unspecified)